Proven­tion Bio takes a $125M loan to ad­vance Eli Lil­ly’s once-re­ject­ed di­a­betes drug

Amidst the on­go­ing biotech mar­ket slow­down, com­pa­nies are try­ing var­i­ous ways to stay afloat. Some are go­ing pub­lic, and some are tak­ing on debt.

The newest en­trant to the bor­row­ers’ club is New Jer­sey-based Proven­tion Bio, which has se­cured a term loan fa­cil­i­ty of up to $125 mil­lion with Her­cules Cap­i­tal.

The fund­ing will be avail­able in five tranch­es, with the first tranche of $25 mil­lion drawn at clos­ing. The com­pa­ny has the op­tion to draw the sec­ond tranche of $40 mil­lion up­on ap­proval of teplizum­ab, sub­ject to cer­tain con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER